Dihexa for Huntington’s Disease: AMT-130, WVE-003, Votoplam & the 2026 UK Review

Around 7,000 people in the UK live with diagnosed Huntington’s disease under Huntington’s Disease Association care, with a community prevalence of roughly 1 in 10,000. Many thousands more are gene-positive but pre-manifest, having received predictive testing through one of the NHS clinical-genetics centres. HD is the prototype autosomal-dominant, fully penetrant, single-gene neurodegenerative disease: a CAG-repeat expansion in HTT on chromosome 4 produces a toxic mutant huntingtin protein whose effects converge on the striatum — specifically on the GABAergic medium spiny neurons of the caudate and putamen — with progressive motor (chorea, dystonia, bradykinesia), cognitive (executive dysfunction, slowed processing, eventual dementia) and psychiatric (depression, irritability, apathy, psychosis) features. The 2025-2026 window has been the most consequential year in HD therapeutics in decades. uniQure’s AAV-delivered microRNA gene therapy AMT-130, with the Cardiff Advanced Neurotherapies Centre as the only UK surgical site and the UCL Huntington’s Disease Centre leading the clinical work, reported a remarkable ~75% slowing of disease progression on a propensity-matched external-control comparator. The FDA’s March 2026 Type-A meeting outcome, however, asked for an additional sham-surgery-controlled Phase 3 before any BLA. The Wave Life Sciences WVE-003 SELECT-HD antisense oligonucleotide showed the first clinical demonstration of allele-selective mutant huntingtin lowering with preservation of wild-type protein. The PTC Therapeutics PTC518 / votoplam PIVOT-HD 24-month extension showed dose-dependent slowing of Stage 2 progression (52% at the 10 mg dose), with the Novartis-led INVEST-HD Phase 3 now under way. Where does Dihexa — a positive modulator of the HGF/c-Met system, downstream of the BDNF-deficient striatal biology that defines HD — sit in this rapidly maturing 2026 picture? An honest, rigorous UK evidence review.

Huntington’s Disease in the UK 2026: 7,000 Diagnosed Cases, A Monogenic, Fully Penetrant Disease

Huntington’s disease is the prototype autosomal-dominant, fully penetrant, single-gene neurodegenerative disease. The Huntington’s Disease Association currently supports approximately 7,000 people in the UK living with diagnosed HD. Brain Research UK estimates the community prevalence at roughly 12 per 100,000 adults, broadly consistent with primary-care studies. NHS Health Education England’s GeNotes resource uses a working figure of 1 in 10,000 for the UK.

Counting gene-positive pre-manifest individuals (CAG ≥40 but no diagnosable motor signs) and at-risk first-degree relatives who have not had predictive testing, the broader HD-affected UK population is several-fold larger. The 2026 picture in the UK clinical-genetics service is one of slowly rising uptake of predictive testing, partly because the disease-modifying pipeline (AMT-130, WVE-003, votoplam) is increasingly perceived as offering real options for gene-positive pre-manifest carriers within the next decade.

HD typically manifests in mid-life (median onset 35-44 years), with juvenile HD (JHD; onset <20 years, often paternally inherited large CAG expansions) and late-onset HD (onset >60 years, smaller expansions in the 36-39 reduced-penetrance range) at the extremes. The mean disease duration from diagnosis to death is around 15-20 years. Cause of death is most commonly aspiration pneumonia or cardiovascular disease secondary to advanced motor decline.

The Biology of Huntington’s Disease: Mutant Huntingtin, the Striatum & Medium Spiny Neurons

The HD molecular cascade is exceptionally well characterised — arguably the best-mapped neurodegenerative disease at the gene level.

The HTT Gene and the CAG Expansion

The HTT gene on chromosome 4p16.3 contains a CAG trinucleotide repeat in exon 1 that encodes a polyglutamine (polyQ) tract in the huntingtin protein. CAG lengths up to 26 are normal; 27-35 are intermediate (no HD risk to carrier, slight risk of paternal expansion); 36-39 are reduced-penetrance (some carriers manifest, some do not); ≥40 are fully penetrant. The expanded protein misfolds, aggregates, gains toxic functions and partially loses its normal cellular roles (which include vesicular transport, autophagy regulation and neurotrophic-factor handling).

Somatic Instability & the “Real” Age of Onset

A major advance in HD biology since the 2015-2020 GWAS work (the GeM-HD consortium) is the recognition that somatic expansion of the CAG repeat — ongoing repeat instability in vulnerable neurons — drives onset more than the inherited length alone. Variants in DNA mismatch-repair genes (MSH3, FAN1, PMS1, LIG1) modify HD age of onset by altering somatic instability. This biology underlies a wave of next-generation HD therapeutics targeting somatic expansion itself — programmes that sit conceptually upstream of HTT-lowering approaches.

Medium Spiny Neurons: The Vulnerable Cell

The HD-vulnerable cells are the GABAergic medium spiny neurons (MSNs) of the caudate and putamen, accounting for ~95% of striatal neurons. They receive massive glutamatergic input from cortex (corticostriatal projections) and dopaminergic input from substantia nigra. MSN loss begins decades before clinical onset (visible as caudate atrophy on volumetric MRI) and produces the cardinal motor and cognitive features of HD. The medium-spiny-neuron biology is what links HD to the wider basal-ganglia neurodegeneration story.

The BDNF Corticostriatal Axis

The single most consistent trophic deficit in HD is loss of BDNF support to the striatum. BDNF is produced predominantly in cortical neurons and shipped via anterograde axonal transport down corticostriatal projections, where it binds TrkB receptors on MSN dendritic spines to support survival and plasticity. Mutant huntingtin reduces BDNF transcription, impairs axonal transport, and disrupts post-synaptic TrkB signalling. The 2025 Neurobiology of Disease BDNF-in-HD review consolidates the evidence. Restoring BDNF activity by direct delivery, viral overexpression or small-molecule TrkB agonists has neuroprotective effects in R6/2, Q175 and other HD mouse models. The systemic recombinant BDNF delivery in R6/2 mice remains a foundational reference. For the Dihexa-relevant axis see Dihexa vs BDNF.

Microglia, Neuroinflammation & the Synaptic Endpoint

Striatal microglia in HD adopt a chronically reactive phenotype that contributes to synaptic loss. PET imaging with TSPO ligands shows increased microglial activation in pre-manifest carriers years before clinical onset. As in vascular dementia, FTD and Lewy body dementia, the final common path of neurological decline is synaptic loss, with reactive microglia and astrocytes contributing materially.

Cognitive & Psychiatric Features

HD is not primarily a motor disease. Executive dysfunction, slowed information processing, impaired procedural learning and psychiatric symptoms (depression, irritability, apathy, obsessionality, occasional psychosis) often predate motor signs by years. Cognitive change in HD overlaps with the broader frontostriatal-circuit dysfunction seen in Parkinson’s disease. The eventual dementia is profound and is part of the broader cognitive-decline landscape covered in our MCI & brain-aging review.

The HGF/c-Met System & the Synaptogenic Case for HD

The hepatocyte growth factor (HGF)/c-Met system is a developmental and adult-brain trophic signalling pathway with documented roles in neuronal survival, synaptogenesis, microglial polarisation and vascular remodelling. Benoist and colleagues (2014) demonstrated that the procognitive and synaptogenic effects of angiotensin IV-derived peptides — the class to which Dihexa belongs — depend on activation of HGF/c-Met. The relevance to HD biology is partial and indirect rather than direct (no head-on HD-mouse-model HGF papers parallel the BDNF literature), but the convergence points are clear.

HGF/c-Met on Striatal Neurons

HGF/c-Met signalling has been shown to support GABAergic interneurons in cortex and striatum, glutamatergic terminals at corticostriatal synapses, and to engage the PI-3K/AKT survival pathway that mutant huntingtin disrupts in MSNs. The 2010 Journal of Neuroscience paper on astrocyte-mediated HGF supplementation restoring GABAergic interneurons and correcting reversal-learning deficits remains a foundational data point. The 2023 Life Science Alliance paper shows that the related hepatoma-derived growth factor (HDGF) is expressed at lower levels in HD-vulnerable DARPP-32+ MSNs than in HD-resistant cholinergic interneurons, broadly consistent with a trophic-deficit framework.

HGF/c-Met and Synaptic Plasticity

HGF/c-Met promotes dendritic spine formation, synaptogenesis and long-term potentiation. The downstream signalling cascade (PI-3K/AKT, ERK/MAPK, dendritic spine cytoskeletal regulation) overlaps materially with the BDNF/TrkB cascade that is most consistently impaired in HD. The mechanistic implication is that a positive HGF/c-Met modulator could engage the same final synaptic substrate that BDNF restoration engages, by a parallel rather than identical route.

HGF/c-Met on Microglia

HGF supports microglial polarisation away from pro-inflammatory states — relevant to HD’s chronic striatal microglial reactivity. This is, again, a parallel mechanism to the BDNF/TrkB axis rather than identical, and contributes to the broader case that HGF/c-Met-modulators sit in the same therapeutic neighbourhood as trophic-factor restoration.

HGF/c-Met on the Cerebrovascular Bed

HGF/c-Met supports cerebral vascular integrity and blood-brain-barrier function, with relevance to the broader vascular-cognitive-impairment story covered in our vascular dementia review. Vascular changes are not central to HD pathology but they matter mid-late disease in older patients with comorbid cerebrovascular load.

The Direct BDNF Comparison

The most useful comparison for HD readers is to Dihexa vs BDNF. BDNF deficiency is the most consistent trophic deficit in HD; Dihexa engages a partly parallel downstream synaptic-plasticity machinery via HGF/c-Met. Neither delivers a direct HTT-lowering effect — the disease-modifying lever that AMT-130, WVE-003 and votoplam pull. The case for Dihexa in HD is therefore at most adjunctive-trophic, and the case is mechanistic rather than evidence-based.

AMT-130: The uniQure AAV Gene Therapy — The Defining 2025-2026 HD Story

The single most important 2025-2026 HD therapeutic narrative is uniQure’s AMT-130. It is the first gene therapy ever tested in Huntington’s disease patients, and the first investigational HD drug to produce a clear, durable, multi-year disease-progression slowing signal.

Mechanism

AMT-130 is a one-time stereotactic intra-striatal injection of an AAV serotype 5 vector encoding a microRNA targeting the HTT mRNA. Once expressed in striatal cells, the microRNA recruits the cell’s RNA-induced silencing complex (RISC) to degrade HTT messenger RNA. As Cardiff University’s explanation puts it: the AMT-130 RNA binds the cell’s own huntingtin RNA, summons an enzyme to destroy it, and the message is permanently deleted. The protein production falls. The therapy is non-selective — both mutant and wild-type huntingtin are lowered — but the magnitude of mutant-huntingtin reduction has been the design priority.

Trial Design

The Phase 1/2 programme enrolled around 39 patients across US and European centres — with the Cardiff Advanced Neurotherapies Centre (ANTC) as the sole UK surgical site, and the UCL Huntington’s Disease Centre leading much of the UK clinical work. Two doses were tested. UCLH’s announcement of the first-in-human UK dosing came in 2020, and the first patients are now at 36-month follow-up.

The 75% Slowing Signal

The September 2025 UCL announcement — co-released by uniQure — reported that patients receiving the high-dose treatment experienced approximately 75% less progression on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months, versus a propensity-matched external-control cohort drawn from ENROLL-HD. The accompanying UCLH release framed this as the first time any drug trial has reported continuing, statistically significant slowing of HD progression. Plasma and CSF neurofilament light fell, consistent with reduced neuronal injury. Open Access Government and the UK Dementia Research Institute covered the announcement in plain language.

Safety

AMT-130 is delivered by MRI-guided stereotactic neurosurgery; serious adverse events have been few, and there has been no recurrence of the high-dose suspension events seen earlier in the programme’s history. The procedural risk is non-trivial but, in context, lower than many systemic-immunosuppression-requiring gene therapies for systemic diseases.

The March 2026 FDA Type-A Meeting — A BLA Delay

uniQure’s post-September-2025 plan was to file a Biologics License Application (BLA) in Q1 2026 supported by the 36-month data plus the external-control comparator. On 3 November 2025 uniQure announced it was no longer aligned with the FDA on the regulatory pathway. On 2 March 2026, uniQure issued its regulatory update: in the Type-A meeting, the FDA stated that it cannot agree that the Phase 1/2 data compared to an external control are sufficient as primary evidence of effectiveness for marketing authorisation. The FDA strongly recommended a prospective, randomised, double-blind, sham-surgery-controlled Phase 3. The HDBuzz commentary — the long-standing patient-and-clinician-facing HD news source — captured the community’s mixed reaction.

Next Steps

uniQure plans a Type-B meeting with the FDA in Q2 2026 to discuss potential Phase 3 study designs, including options that might shorten the timeline (smaller sham-controlled designs with adaptive elements, alternative endpoints, real-world-data integrations). The HDBuzz follow-up four weeks later is the most honest community summary of where the programme stands. Bloomberg covered the unprecedented patient-advocate push for FDA approval based on the existing data.

UK Context

The Cardiff ANTC remains the only UK surgical site for AMT-130. If a sham-controlled Phase 3 launches in 2026-2027, UK participation through Cardiff and the wider Cardiff Huntington’s Disease Centre current-studies portfolio is the most likely route in for UK patients. The Health and Care Research Wales announcement provides additional UK-specific context.

WVE-003 (Wave Life Sciences) & the SELECT-HD Allele-Selective Story

The conceptually most elegant HD therapeutic strategy is allele-selective lowering of mutant huntingtin while preserving wild-type huntingtin (which has essential cellular functions). Wave Life Sciences’ WVE-003 is the first clinical-stage drug to demonstrate this in patients.

Mechanism

WVE-003 is an intrathecally delivered antisense oligonucleotide (ASO) targeting a single-nucleotide polymorphism (SNP3, rs362307) that, in a substantial subset of HD patients, sits exclusively on the mutant HTT allele. By targeting the SNP rather than the gene as a whole, WVE-003 knocks down only mutant HTT mRNA while leaving wild-type HTT intact. The eligible patient population is roughly 40% of HD patients carrying the matching SNP3 allele — identified by routine genotyping.

The SELECT-HD Phase 1b/2a Results

The multidose 30 mg cohort showed a statistically significant 46% mean reduction in CSF mutant huntingtin protein at 12 weeks post-treatment, durable through the 28-week study period, with preservation of wild-type huntingtin (no significant change). No Serious Adverse Events were reported. The NeurologyLive coverage is the most accessible clinical summary.

The Caudate Atrophy Signal

A statistically significant correlation between mHTT lowering and slowing of caudate atrophy — the imaging biomarker most predictive of clinical outcome in HD — was reported. This is exactly the kind of disease-modifying imaging signal regulators have asked for in earlier HD programmes, and it strengthens the case for an accelerated approval pathway.

Next Steps

Wave is engaging regulators on a registration path that may support potential accelerated approval, and submitted an opt-in package to its partner Takeda. The BioPharma Dive coverage details the partnership dynamics. UK enrolment for any expanded WVE-003 trial would likely run through the UCL/UCLH and Cardiff HD services.

Why Allele Selectivity Matters: The Tominersen Lesson

Roche’s tominersen, the first HD ASO in Phase 3, lowered both mutant and wild-type huntingtin and failed GENERATION HD1 in 2021 partly because the high-dose arm showed a signal of clinical worsening. The community interpretation: non-selective HTT lowering at high dose may deplete wild-type huntingtin past a tolerable floor. The lower-dose, less-frequent GENERATION HD2 is testing whether a gentler non-selective regimen in earlier-stage HD can work. WVE-003’s allele selectivity provides a different solution to the same problem: lower only the toxic protein.

PTC518 (Votoplam) & the PIVOT-HD 24-Month Extension

PTC Therapeutics’ votoplam (PTC518) is the only oral, brain-penetrant, systemically delivered HTT lowerer currently in late-stage HD development.

Mechanism

Votoplam is an oral small-molecule splicing modulator that promotes the inclusion of a normally skipped pseudo-exon (containing a premature termination codon) in the HTT pre-mRNA. This produces a truncated, rapidly degraded transcript and reduces mature HTT protein production. The lowering is non-selective — both mutant and wild-type HTT — but the oral, dose-titratable, brain-penetrant pharmacology contrasts cleanly with the surgical (AMT-130) and intrathecal (WVE-003) alternatives.

PIVOT-HD Primary Results (2025)

The Phase 2 PIVOT-HD primary readout in Stage 2 and Stage 3 HD met its primary endpoint of HTT-protein reduction in blood (p<0.0001) at Week 12 with favourable safety. The 12-month follow-up showed dose-dependent blood-HTT lowering: 23% at 5 mg in both Stage 2 and Stage 3 patients; 39% at 10 mg in Stage 2; 36% at 10 mg in Stage 3.

The April 2026 24-Month Extension

On 28 April 2026, PTC reported positive topline results from the 24-month interim of the PIVOT-HD long-term extension in Stage 2 participants:

• 10 mg dose: 52% slowing of progression on cUHDRS versus a propensity-weighted natural-history cohort.
• 5 mg dose: 28% slowing on cUHDRS.
• NfL: No treatment-related neurofilament-light increases; mean NfL levels remained below baseline at 24 months in both dose cohorts — in contrast to the natural-history trajectory of rising NfL.

The NeurologyLive coverage articulates the external-control comparator caveat: the same propensity-weighted natural-history approach that the FDA pushed back on for AMT-130 applies here too, and a properly randomised Phase 3 remains the gold standard.

The Novartis INVEST-HD Phase 3

Under the 2024 PTC-Novartis licensing agreement, Novartis has now launched the global INVEST-HD Phase 3 trial of votoplam in Stage 2 HD. This is the first true late-stage trial of a systemic, oral HTT-lowering therapy in HD. UK enrolment is likely through the UCL/UCLH and Cardiff centres and the wider NIHR Be Part of Research portal.

Where Does This Leave AMT-130?

The unspoken implication of the votoplam extension data is that an oral, brain-penetrant, dose-titratable systemic HTT lowerer may achieve magnitude-of-benefit results comparable to or better than the surgical AAV approach, with less procedural risk. AMT-130 may retain advantages in (a) one-and-done dosing rather than chronic daily oral therapy, (b) the ability to bypass the BBB and target the striatum directly at high concentration, and (c) the durability of expression. But the field’s 2026 momentum, post-FDA March 2026 setback for AMT-130, has tilted toward oral and intrathecal alternatives.

The Wider 2026 HD Pipeline & Historical Lessons

Tominersen (Roche/Ionis) — GENERATION HD1 Failure, GENERATION HD2 Ongoing

Roche’s tominersen, a non-allele-selective intrathecal HTT-lowering ASO, failed GENERATION HD1 in 2021 with a worsening signal in the every-8-week dosing arm. Roche subsequently launched GENERATION HD2, testing lower doses (60 mg, 100 mg) at less frequent dosing in earlier-stage HD, with readouts expected later in 2026-2027.

Branaplam (Novartis) — Terminated

Novartis discontinued the HD branaplam programme (VIBRANT-HD) in 2022 after peripheral neuropathy safety signals; the small-molecule splicing-modulator approach has now been picked up successfully by PTC’s votoplam with a different mechanism and tolerability profile.

SAGE-718 (Dalzanemdor) — SURVEYOR-HD Failure

SAGE-718, an NMDA-receptor positive allosteric modulator developed for HD cognitive symptoms, failed the SURVEYOR-HD trial in 2024 and the wider DIMENSION (early Alzheimer’s) and LIGHTWAVE (Parkinson’s disease cognitive impairment) programmes were also wound down. The lesson: pure symptomatic NMDA modulation in HD cognition has not delivered.

Somatic-Expansion-Targeting Programmes

The newer wave of HD therapeutics targets the somatic-expansion machinery itself — MSH3 inhibitors (LoQus23, Rgenta) and related approaches aim to slow ongoing CAG expansion in vulnerable neurons. Early data are exploratory; these programmes sit conceptually upstream of HTT lowering and may eventually combine with it.

Other AAV Programmes

Voyager Therapeutics, Spark Therapeutics and others have HD AAV programmes at preclinical or early clinical stage. None has produced data approaching the AMT-130 36-month signal.

Fosgonimeton (ATH-1017) & the HGF/c-Met Adjacent Field

The closest clinical-stage HGF/c-Met-modulator relative to Dihexa, fosgonimeton (ATH-1017), was developed by Athira Pharma for Alzheimer’s disease, Parkinson’s disease dementia (SHAPE trial), and dementia with Lewy bodies. Fosgonimeton was not tested in Huntington’s disease. The Athira programme has been substantially curtailed; there is no near-term HD-specific HGF-modulator candidate behind it.

Symptomatic Chorea: VMAT2 Inhibitors

For symptomatic chorea management, the three FDA-approved VMAT2 inhibitors are tetrabenazine (longest-established, NHS workhorse, mood-side-effect risk), deutetrabenazine (SD-809, Austedo) (improved half-life, better-tolerated), and valbenazine (Ingrezza) (KINECT-HD trial). In the UK, tetrabenazine remains the most widely prescribed; deutetrabenazine availability via specialist commissioning has expanded; valbenazine UK availability is limited.

HD Care in the UK in 2026: NICE, NHS & the HDA Specialist Advisor Network

NICE Position

There is no NICE-recommended disease-modifying treatment for Huntington’s disease in 2026. Symptomatic management for chorea uses tetrabenazine (with deutetrabenazine increasingly available); psychiatric symptoms are managed with SSRIs, mirtazapine, mood stabilisers and low-dose antipsychotics where indicated. NHS England commissions specialist HD services through the rare-disease pathway.

Specialist HD Clinics in the UK

The UK’s principal specialist HD clinical and research centres in 2026 include:

• UCL Huntington’s Disease Centre & UCLH (Professor Sarah Tabrizi’s group; lead UK AMT-130 clinical site).
• Cardiff University Huntington’s Disease Centre & the Advanced Neurotherapies Centre (ANTC) — the only UK surgical site for AMT-130.
• Manchester (Salford Royal HD service).
• Glasgow and Aberdeen (Scotland; Scottish Huntington’s Association partnership).
• Belfast (Northern Ireland regional service).
• Birmingham, Sheffield, Cambridge and additional regional centres via the wider UK HD network.

Multidisciplinary Care

HD multidisciplinary care typically includes neurology, clinical genetics, psychiatry, neuropsychology, speech and language therapy (early dysarthria/dysphagia screening), physiotherapy, occupational therapy, dietetics, specialist nursing and end-of-life planning. The HDA’s Specialist Advisor service is the most distinctive UK feature: regionally embedded HD-specialist support workers providing continuity from pre-symptomatic through end-of-life. The Mental Capacity Act 2005 considerations — capacity, advance decisions, Lasting Power of Attorney — are particularly important in HD given its psychiatric and cognitive features.

Predictive Genetic Testing in the UK

Predictive testing for HD in the UK runs through NHS clinical-genetics centres under a structured multi-session counselling protocol (the Huntington’s Disease Predictive Test Protocol). Testing requires informed adult consent; pre-test counselling typically involves 2-3 sessions over weeks-to-months. Insurance implications are governed by the Code on Genetic Testing and Insurance, which currently allows insurers to ask about positive predictive HD tests for life-insurance policies above £500,000. Pre-implantation genetic diagnosis (PGD) for reproductive choice is available on the NHS in England and Wales through licensed clinics.

UK Support Organisations

Key UK HD support organisations include:

• Huntington’s Disease Association (HDA) — England and Wales; Specialist Advisor service; family support line.
• Scottish Huntington’s Association — Scotland services and Specialist Advisors.
• Brain Research UK — research funding and information.
• UK Dementia Research Institute — HD-relevant research portfolio.
• HDBuzz — plain-language HD research journalism, internationally respected, UK-friendly.
• CHDI Foundation — the principal global HD research funder; ENROLL-HD sponsor.
• ENROLL-HD and HDClarity — the global HD observational platform and CSF-biomarker study.

2026 HD News: What Is Actually Happening This Year

The defining 2025-2026 HD news beats:

• September 2025: UCL and uniQure announce the AMT-130 75% slowing signal at 36 months; Cardiff University releases its ANTC role; UCLH issues its 75% slowing announcement.
• November 2025: uniQure announces it is no longer aligned with the FDA on the AMT-130 regulatory pathway.
• January 2026: Bloomberg reports HD-patient-advocate pressure on the FDA to approve AMT-130 on existing data.
• February 2026: Kinesis Magazine publishes an in-depth feature on the UCL gene-therapy breakthrough.
• 2 March 2026: uniQure issues its Type-A meeting outcome — FDA requires sham-controlled Phase 3.
• March-April 2026: HDBuzz and its four-week-later follow-up become the community’s authoritative response.
• April 2026 (AAN Chicago): Huntington’s sessions cover both the AMT-130 community response and the wider HTT-lowering pipeline.
• 28 April 2026: PTC Therapeutics reports the PIVOT-HD 24-month extension — 52% slowing at 10 mg in Stage 2; Novartis INVEST-HD Phase 3 active.
• Q2 2026: uniQure’s Type-B meeting to discuss Phase 3 design.
• UK trial recruitment 2026: via NIHR Be Part of Research, the UCL HD Centre and the Cardiff HD Centre current-studies page.

For broader cognitive-neurology 2026 context, see the Lewy body dementia review (CervoMed neflamapimod AAN 2026 basal-forebrain MRI), the vascular dementia review (UCLA April 2026 brain-repair breakthrough), the FTD review (latozinemab INFRONT-3 failure; Emma & Bruce Willis Fund), the Alzheimer’s research review, the Parkinson’s disease review and the diabetic brain fog review (EVOKE / EVOKE+ semaglutide-in-Alzheimer’s failure).

Practical Realities: If a Family Affected by HD Is Considering Dihexa

We are not clinicians. This is an evidence-based explainer. The question is asked, by people in genuinely difficult positions — gene-positive adults watching parents decline, family carers, occasionally people in early symptomatic disease. An honest answer is more useful than silence.

HD-Specific Considerations

• Trial eligibility. The single most important practical consideration in 2026. Concurrent unapproved research-chemical use will likely exclude a person from AMT-130, WVE-003, votoplam INVEST-HD or any other registrational HD trial. The probability that one of these enters NHS-accessible care in the next 5-10 years is materially non-zero.
• Psychiatric vulnerability. HD carries elevated rates of depression, irritability, impulsivity and suicidality. Any compound that perturbs sleep, mood or cognition adds risk on a baseline that is already stressed.
• Cognitive monitoring. HD cognitive change is progressive on a years-to-decades timescale. Distinguishing a real effect of any intervention from baseline progression is genuinely hard, even for trial methodologists. An informal personal “trial” is even harder.
• Polypharmacy. A typical mid-stage HD patient may be on tetrabenazine or deutetrabenazine, an SSRI, mirtazapine, an antipsychotic, a hypnotic, a laxative regimen and a thickener-/feeding-modification protocol. Adding Dihexa adds an uncharacterised interaction surface.
• Capacity considerations. Mid-late HD impairs capacity progressively. Mental Capacity Act 2005 considerations apply explicitly. A family with full health-and-welfare LPA still cannot consent to unlicensed-drug use on the patient’s behalf without a prescribing clinician.
• Pre-manifest carriers. The temptation for a gene-positive but pre-symptomatic adult to “do something” is understandable. The evidence-based answers are: enrol in ENROLL-HD, engage with the UCL or Cardiff service, optimise modifiable risk factors per the Lancet Commission framework, and wait for the trial pipeline. Unsupervised peptide use will probably exclude trial participation.

Dosing Considerations Specific to HD

If — against advice — an informed adult with capacity proceeds, the principles in the general dosage guide apply with extra caution:

• Start at a markedly lower dose than community averages; titrate slowly across weeks.
• Document baseline cognition (MoCA, ACE-III, ideally a UHDRS cognitive battery) before starting, then at six and twelve weeks.
• Track mood (PHQ-9, GAD-7) and any new behavioural change. HD irritability is real and matters.
• Do not stop tetrabenazine, deutetrabenazine, valbenazine, antidepressants or antipsychotics without your prescriber.
• Stop immediately for any new severe mood change, suicidality, psychosis, motor deterioration, falls or sleep disruption.
• Have a clinician aware of the experiment, even if they cannot endorse it.

Monitoring

Beyond cognition, thoughtful monitoring includes baseline and follow-up blood pressure, weight, mood scales, sleep diary, falls diary, swallowing self-assessment, standard liver and renal panels. Where research-grade biomarkers are accessible (NfL via specialist research blood draw via ENROLL-HD participation), they provide a more objective progression signal than clinical impression.

When to Stop Immediately

New severe mood deterioration or suicidal ideation, new psychosis, severe motor deterioration, new dystonia or seizures, falls, severe sleep disturbance, signs of mania, any new or worsening dysphagia. None of these is theoretical; all are part of the baseline HD picture and can be plausibly destabilised by any new agent.

The Evidence-Based 2026 Plan for HD-Affected UK Families

If a UK family member has HD or is gene-positive in 2026, the evidence-based prioritisation is approximately:

1. Get a diagnostic, prognostic and genetic baseline. Specialist HD service review at UCL/UCLH, Cardiff, Manchester, Glasgow, Aberdeen or Belfast. Clinical genetics for confirmed CAG count. Cognitive baseline. Mood and psychiatric review. Functional baseline (UHDRS where appropriate).
2. Engage HDA support. A Huntington’s Disease Association Specialist Advisor (or Scottish Huntington’s Association equivalent) provides decades of pragmatic, locally-embedded HD-specific guidance that no general service can match.
3. Get on the trial pipeline. Register with ENROLL-HD via your specialist clinic. Watch the AMT-130 sham-controlled Phase 3 development. Watch the Novartis INVEST-HD votoplam Phase 3 recruitment. Watch WVE-003 Wave-Takeda registrational plans. Sign up for the NIHR Be Part of Research portal.
4. Optimise NICE/NHS symptomatic care. Tetrabenazine, deutetrabenazine or valbenazine for chorea where appropriate. SSRIs and mirtazapine for mood. Sleep and weight management. Specialist swallowing assessment from mid-disease.
5. Modifiable risk factors. The 2024 Lancet Commission’s 14 modifiable dementia risk factors (covering ~45% of dementia cases) are relevant for HD too: hearing, vision, hypertension, obesity, smoking, depression, physical inactivity, diabetes, alcohol, traumatic brain injury, air pollution, social isolation, LDL cholesterol, less education. Cardiovascular health matters as much in HD as in any dementia.
6. Caregiver care. HDA Specialist Advisor support for carers, peer groups, respite, Mental Capacity Act planning, Lasting Power of Attorney, advance decisions. HD is harder on carers than most dementias because of its psychiatric features and the long pre-decline awareness.
7. Lifestyle. Mediterranean-style diet, regular physical activity (including exercise programmes specifically studied in HD), sleep hygiene, social connection. None is dramatic; collectively, they remain the most evidence-based brain-health intervention available.
8. Predictive testing decisions. If pre-manifest and considering testing, three or more counselling sessions via your NHS clinical-genetics centre. Insurance and reproductive implications discussed up front. PGD where reproductive choice is relevant.
9. Established adjuncts where evidence exists: physiotherapy, occupational therapy, speech and language therapy, dietetics. HD-specific exercise programmes have a real evidence base for functional preservation.
10. Unlicensed peptides last, if at all, and only with prescriber oversight and explicit recognition that they may close trial doors. The honest 2026 statement is that no human Dihexa data exist in any HD population.

The Bottom Line: A Real Disease-Modifying Pipeline, A Plausible Trophic Adjunct & Zero Human Dihexa Data

Huntington’s disease in 2026 is, against decades of expectation, the neurodegenerative disease with the most encouraging late-stage pipeline in its history. AMT-130 has produced a 75% slowing signal that is plausibly real and is now constrained by the appropriately conservative FDA position requiring a sham-controlled Phase 3. WVE-003 has demonstrated allele-selective lowering of mutant huntingtin alone — the conceptually most elegant solution to the “don’t deplete wild-type” problem — and is heading toward an accelerated-approval discussion. Votoplam has demonstrated 52% slowing at the 10 mg dose in Stage 2 patients at 24 months, with a Novartis-led INVEST-HD Phase 3 active. The mechanistic case for an HGF/c-Met-modulator like Dihexa in HD — downstream of the BDNF axis that is the most consistent trophic deficit in HD biology — is conceptually coherent. The trial-grade evidence is zero.

For UK families: specialist HD-clinic care first. HDA support throughout. Trial-pipeline engagement second. Evidence-based supportive care throughout. Unsupervised peptide use essentially last, and only with explicit recognition that it may exclude participation in the very trials that are HD’s best near-term hope. The honest 2026 answer to “does Dihexa help Huntington’s disease?” is: nobody knows, no one has tested it, and the disease-modifying pipeline has more credible late-stage momentum than at any point in HD’s history.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Parkinson’s Disease — the basal-ganglia neurodegeneration neighbour; shared dopaminergic and synaptic biology.
• Dihexa for Lewy Body Dementia (DLB) — the alpha-synucleinopathy story; CervoMed neflamapimod RewinD-LB extension and AAN 2026.
• Dihexa for Frontotemporal Dementia (FTD) — the latozinemab Phase 3 failure and the Emma & Bruce Willis Fund.
• Dihexa for Vascular Dementia & VCI — UCLA April 2026 brain-repair breakthrough; HGF/c-Met angiogenesis.
• Dihexa for ALS & MND — HGF/c-Met motor-neuron-protection; another monogenic-dominated neurodegeneration field.
• Dihexa & Alzheimer’s Research — the Wright laboratory origin story; 2026 NICE lecanemab and donanemab rejections.
• Dihexa for MCI & Brain Aging — synaptic-loss case and Lancet Commission’s 14 modifiable risk factors, applicable to HD too.
• Fosgonimeton & Athira — the closest clinical-stage HGF/c-Met-modulator relative; SHAPE PDD signal.
• Dihexa vs BDNF — the corticostriatal BDNF axis in HD, the synaptic-plasticity comparison.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines, microglial polarisation.
• Dihexa for Depression & Mood — HD-relevant given the high psychiatric symptom load.
• Dihexa for Anxiety & Chronic Stress — another HD-relevant mood adjunct.
• Dihexa, Sleep & Memory Consolidation — HD sleep dysregulation context.
• Dihexa for TBI & Concussion — falls-related TBI risk in mid-late HD.
• Dihexa for Stroke Recovery & PSCI — the synaptic-recovery framework.
• Dihexa for Multiple Sclerosis (MS) — another HGF/c-Met-relevant neurodegeneration review.
• Dihexa for Chemo Brain (CICI) — another cognitive-recovery indication.
• Dihexa for Long COVID Brain Fog — shared microglial-neuroinflammation substrate.
• Dihexa for PTSD & Complex PTSD — the fear-extinction synaptic-plasticity rationale.
• Dihexa for Diabetic Brain Fog — the EVOKE / EVOKE+ Alzheimer’s failure parallel.
• Dihexa for ADHD — prefrontal-cortex angle on the broader synaptic story.
• Dihexa for Menopause Brain Fog — differential considerations in women presenting with cognitive change.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling protocols.
• Dihexa Stacking Guide — combination considerations relevant to HD polypharmacy.
• Dihexa for Cognitive Enhancement — the broader cognition conversation.
• Benefits Overview — the broader claimed-benefit landscape, evidence-rated.
• Dosage Guide — community dose ranges and considerations.
• Side Effects & Risks — the general safety picture, including HD-relevant polypharmacy.
• UK Legal Status — where Dihexa sits in UK law.
• Research & Studies — the human and animal evidence base.
• Dihexa vs Other Nootropics — comparisons with Semax, Selank, Noopept, BPC-157, cerebrolysin and citicoline.
• Glossary — technical terms used on this page.
• Full Site FAQ — the broader question set across the site.

External Authoritative Sources Cited

• UCL News. Gene therapy appears to slow Huntington’s disease progression (September 2025).
• UCLH NHS Foundation Trust. Huntington’s Disease Gene Therapy Shows 75 Per Cent Slowing of Disease Progression.
• Cardiff University News. Gene therapy appears to slow Huntington’s disease progression (ANTC).
• UCLH. UCLH launches first-in-human study for Huntington’s Disease.
• Health and Care Research Wales. Wales leads pioneering gene therapy trial shown to slow progression of Huntington’s disease.
• UK Dementia Research Institute. Breakthrough gene therapy brings hope for slowing Huntington’s.
• uniQure. Regulatory Update on AMT-130 for Huntington’s Disease (March 2026).
• HDBuzz. The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy.
• HDBuzz. Additional clarity: what we know 4 weeks after the uniQure news.
• Bloomberg. Huntington’s Advocates Urge FDA to Approve UniQure’s Gene Therapy, AMT-130.
• Kinesis Magazine. A Gene Therapy Breakthrough for Huntington’s Disease — How UCL Researchers Are Transforming the Future of Treatment.
• Wave Life Sciences. Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering.
• NeurologyLive. WVE-003 Shows Allele-Selective Mutant Huntingtin Reduction in Phase 1b/2a SELECT-HD Trial.
• BioPharma Dive. Wave, with new data, plots path forward for Huntington’s drug.
• ClinicalTrials.gov. Study of WVE-003 in Patients With Huntington’s Disease.
• PTC Therapeutics. PTC518 PIVOT-HD Study Achieves Primary Endpoint.
• PTC Therapeutics. Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam (April 2026).
• NeurologyLive. Votoplam Shows Dose-Dependent Slowing of Disease Progression in Stage 2 Huntington Disease.
• Neurobiology of Disease. Brain-Derived Neurotrophic Factor (BDNF) in Huntington’s Disease: Neurobiology and Therapeutic Potential (2025).
• PubMed. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington’s disease.
• Scientific Reports. Decreased BDNF Release in Cortical Neurons of a Knock-in Mouse Model of Huntington’s Disease.
• PMC. Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity.
• Life Science Alliance. Neuroprotective effects of hepatoma-derived growth factor in models of Huntington’s disease.
• Journal of Neuroscience. Astrocyte-Mediated Hepatocyte Growth Factor/Scatter Factor Supplementation Restores GABAergic Interneurons and Corrects Reversal Learning Deficits in Mice.
• Frontiers in Neuroscience. Cortical and Striatal Circuits in Huntington’s Disease.
• Benoist CC et al. The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides are Dependent on Activation of the HGF/c-Met System.
• Wright JW & Harding JW. The Development of Small Molecule Angiotensin IV Analogs to Treat Alzheimer’s and Parkinson’s Diseases. Neuroscience (2015).
• UCL Huntington’s Disease Centre.
• Cardiff University Huntington’s Disease Centre — Current clinical studies.
• Huntington’s Disease Association (HDA UK).
• Scottish Huntington’s Association.
• Brain Research UK — Huntington’s Disease.
• NHS Health Education England Genomics Education Programme — Huntington Disease.
• ENROLL-HD — the global Huntington’s observational platform.
• CHDI Foundation.
• HDBuzz — plain-language Huntington’s disease research news.
• NIHR Be Part of Research Portal.
• Livingston G et al. Dementia Prevention, Intervention, and Care: 2024 Report of the Lancet Standing Commission.